Appili Therapeutics to Present at the 2021 VIRTUAL H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Appili Therapeutics (TSX: APLI, OTCQX: APLIF) announced that CEO Dr. Armand Balboni will present at HC Wainwright’s inaugural BioConnect 2021 virtual conference from January 11-14, 2021. The pre-recorded presentation will be available on demand starting January 11 at 6:00 AM ET for one week. This conference serves as a forum for companies to connect with investors during the JP Morgan Healthcare Conference. Appili focuses on developing novel therapies for life-threatening infections, including advancing clinical trials for the antiviral Avigan® for COVID-19 treatment.

Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that Appili’s CEO Dr. Armand Balboni will participate in HC Wainwright’s Bioconnect 2021 investor event. The virtual conference takes place from January 11 – 14, 2021.

Presentation details are as follows:

• Type: Pre-recorded Company Presentation from Dr. Balboni
• Date: Monday January 11, 2021 (on demand for one week)
• Time: Starting at 6:00 AM ET

About the Conference
This is the inaugural virtual H.C. Wainwright BioConnect Conference. H.C. Wainwright is hosting the event to provide clients with a forum to virtually present to investors during the timeframe of the JP Morgan Healthcare Conference. This event will include Company Presentations, Fireside Chats, Investment Banking Meetings, and Research Meetings.

About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan® (favipiravir) for the worldwide treatment and prevention of COVID-19. The Company is also advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, connect at AppiliTherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005145/en/

FAQ

When will Appili Therapeutics' CEO Dr. Armand Balboni present at the HC Wainwright BioConnect 2021 conference?

Dr. Balboni's presentation will be available on January 11, 2021, starting at 6:00 AM ET.

What is the focus of Appili Therapeutics as a biopharmaceutical company?

Appili Therapeutics focuses on developing anti-infective drugs to address life-threatening infections.

What notable projects is Appili involved in related to COVID-19?

Appili is sponsoring late-stage clinical trials for the antiviral Avigan® (favipiravir) for COVID-19 treatment.

What type of event is the HC Wainwright BioConnect 2021 conference?

It is a virtual conference designed for companies to present to investors during the JP Morgan Healthcare Conference.

What is the aim of Appili's drug development strategy?

The aim is to systematically develop a pipeline of novel therapies to prevent deaths and improve lives from urgent infections.